• 1
    Shelley WB, Arthur RP. The neurohistology and neurophysiology of the itch sensation in man. Arch Dermatol 1957; 76: 296323.
  • 2
    Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4(1): 727.
  • 3
    Scott PV, Fischer HB. Intraspinal opiates and itching: a new reflex? Br Med J (Clin Res Ed) 1982; 284(6321): 10156.
  • 4
    Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988; 33(2): 14960.
  • 5
    Schmelz M. A neural pathway for itch. Nat Neurosci 2001; 4(1): 910.
  • 6
    Ghent CN, Bloomer JR, Klatskin G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and to pruritus. Gastroenterology 1977; 73(5): 112530.
  • 7
    Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974; 109(5): 67881.
  • 8
    Varco RL. Intermittent external biliary drainage for the relief of pruritus in certain chronic disorders of the liver. Surgery 1947; 21: 435.
  • 9
    Huet PM, Rautureau M, Dhumeaux D, et al. The effects of biliary drainage in cholestatic hepatitis. Rev Med Chir Foie 1970; 45: 2718.
  • 10
    Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002; 35(6): 15016.
  • 11
    Bartholomew TC, Summerfield JA, Billing BH, Lawson AM, Setchell KD. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin Sci (Lond) 1982; 63(1): 6573.
  • 12
    Hofmann AF. Rifampicin and treatment of cholestatic pruritus. Gut 2002; 51(5): 7567.
  • 13
    Chanarin I, Szur L. Letter: Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine. Br J Haematol 1975; 29(4): 66970.
  • 14
    Silverberg DS, Iaina A, Reisin E, Rotzak R, Eliahou HE. Cholestyramine in uraemic pruritus. Br Med J 1977; 1(6063): 7523.
  • 15
    Alva J, Iber FL. Relief of pruritus of jaundice with methandrostenolone and speculation on the nature of pruritus in liver disease. Am J Med Sci 1965; 250: 605.
  • 16
    Ghent CN. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. Am J Gastroenterol 1987; 82(2): 1178.
  • 17
    Bergasa NV, Jones EA. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 1995; 108(5): 15828.
  • 18
    Koenigstein H. Experimental study of itch stimuli in animals. Arch Dermatol Syph 1948; 57: 82849.
  • 19
    Scott PV, Fischer HB. Spinal opiate analgesia and facial pruritus: a neural theory. Postgrad Med J 1982; 58(683): 5315.
  • 20
    Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J 1988; 297(6662): 15014.
  • 21
    Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 1992; 103(2): 6305.
  • 22
    Bergasa NV, Alling DW, Vergalla J, Jones EA. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994; 20(1): 8590.
  • 23
    Bergasa NV, Rothman RB, Vergalla J, Xu H, Swain MG, Jones EA. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992; 15(1–2): 2204.
  • 24
    Spivey JR, Jorgensen RA, Gores JG. Serum met-enkephalin levels in patients with primary biliary cirrhosis correlate with severity of disease but not pruritus. Gastroenterology 1992; 102(4): 892A.
  • 25
    Richardson BP. Serotonin and nociception. Ann N Y Acad Sci 1990; 600: 51120.
  • 26
    Harsing LG, Yang H-YT. Serotoninergic regulation of hypothalamic met-enkephalin content. In: Hannin I, ed. New York: Raven, 1984: 16976.
  • 27
    Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996; 16(5): 95860.
  • 28
    Crighton IM, Hobbs GJ, Reid MF. Ondansetron for the treatment of pruritus after spinal opioids. Anaesthesia 1996; 51(2): 199200.
  • 29
    Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991; 25(5): 4003.
  • 30
    Molenaar HA, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998; 36(2): 2204.
  • 31
    McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18(4): 100719.
  • 32
    Hadzigiannis S, Hadzigiannis E, Makris A. A randomised controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). Hepatology 1989; 10(4); 580A.
  • 33
    Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85(1): 1523.
  • 34
    Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med 1991; 324(22): 154854.
  • 35
    Battezzati PM, Podda M, Bianchi FB, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J Hepatol 1993; 17(3): 3328.
  • 36
    Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32(4): 5616.
  • 37
    Vuoristo M, Farkkila M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995; 108(5): 14708.
  • 38
    Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354(9184): 105360.
  • 39
    Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; 1: CD000551.
  • 40
    Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 1992; 15(3): 33644.
  • 41
    Wiesner RH, Ludwig J, Lindor KD, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322(20): 141924.
  • 42
    Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991; 101(5): 13328.
  • 43
    Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 1999; 117(5): 117380.
  • 44
    Hendrickse MT, Rigney E, Giaffer MH, et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117(2): 4007.
  • 45
    Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994; 107(1): 26670.
  • 46
    West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975; 16(2): 938.
  • 47
    Datta DV, Sherlock S. Treatment of pruritus of obstructive jaundice with cholestyramine. Br Med J 1963; 26: 2169.
  • 48
    Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1966; 50(3): 32332.
  • 49
    Javitt NB. Letter: Timing of cholestyramine doses in cholestatic liver disease. N Engl J Med 1974; 290(23): 13289.
  • 50
    Eaves ER, Korman MG. Cholestyramine induced hyperchloremic metabolic acidosis. Aust N Z J Med 1984; 14(5): 6702.
  • 51
    Shojania AM, Grewar D. Hypoprothrombinemic hemorrhage due to cholestyramine therapy. CMAJ 1986; 134(6): 60910.
  • 52
    Shimada H, Mitsuka M, Umezu K. The interaction between MCI-196 (colestimide) and bile acids or other biological substances. Jpn Pharmacol Ther 1996; 24(Suppl.): 6015.
  • 53
    Berg CI. Use of colesevalem hydrochloride (Welchol™) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 2001; 34: 541A.
  • 54
    Miguet JP, Mavier P, Soussy CJ, Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology 1977; 72(5 Part 1): 9246.
  • 55
    Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980; 25(2): 10812.
  • 56
    Yousef IM, Tuchweber B, Vonk RJ, Masse D, Audet M, Roy CC. Lithocholate cholestasis — sulfated glycolithocholate-induced intrahepatic cholestasis in rats. Gastroenterology 1981; 80(2): 23341.
  • 57
    Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94(2): 48893.
  • 58
    Podesta A, Lopez P, Terg R, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36(2): 21620.
  • 59
    Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102(6): 207780.
  • 60
    Woolf GM, Reynolds TB. Failure of rifampin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990; 12(2): 1747.
  • 61
    Bachs L, Pares A, Elena M, Piera C, Rodes J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1(8638): 5746.
  • 62
    Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98(4): 10136.
  • 63
    Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976; 294(20): 11046.
  • 64
    Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50(3): 4369.
  • 65
    Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115(11): 13667.
  • 66
    Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102(2): 5449.
  • 67
    Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995; 123(3): 1617.
  • 68
    Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113(4): 12649.
  • 69
    Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27(3): 67984.
  • 70
    Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000; 118(2): 4312.
  • 71
    Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol 2001; 13(11): 13934.
  • 72
    Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91(5): 10223.
  • 73
    Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986; 1(8491): 1215.
  • 74
    Schwörer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993; 341(8855): 1277.
  • 75
    Schwörer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Invest 1993; 71(8): 65962.
  • 76
    Raderer M, Müller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994; 330(21): 1540.
  • 77
    Schwörer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61(1): 337.
  • 78
    Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10(10): 86570.
  • 79
    Borgeat A, Wilder-Smith O, Mentha G, Huber O. Propofol and cholestatic pruritus. Am J Gastroenterol 1992; 87(5): 6724.
  • 80
    Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104(1): 2447.
  • 81
    Borgeat A, Mentha G, Savioz D, Wilder-Smith OH. Pruritus associated with liver disease: Propofol, a new therapeutic approach? Schweiz Med Wochenschr 1994; 124(15): 64950.
  • 82
    Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis. Lancet 1980; 2(8193): 530.
  • 83
    Cerio R, Murphy GM, Sladen GE, MacDonald DM. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 1987; 116(2): 2657.
  • 84
    Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001; 96(5): 156370.
    Direct Link:
  • 85
    Frezza M, Pozzato G, Chiesa L, Stramentinoli G, Di Padova C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 1984; 4(2): 2748.
  • 86
    Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 1990; 99(1): 2115.
  • 87
    Ribalta J, Reyes H, Gonzalez MC, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology 1991; 13(6): 10849.
  • 88
    Everson GT, Ahnen D, Harper PC, Krawitt EL. Benign recurrent intrahepatic cholestasis: treatment with S- adenosylmethionine. Gastroenterology 1989; 96(5 Part 1): 13547.
  • 89
    Sokol RJ, Devereaux M, Khandwala RA. Effect of dietary lipid and vitamin E on mitochondrial lipid peroxidation and hepatic injury in the bile duct-ligated rat. J Lipid Res 1991; 32(8): 134957.
  • 90
    Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997; 26(1): 13542.
  • 91
    Watson JP, Jones DE, James OF, Cann PA, Bramble MG. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol 1999; 14(10): 103440.
  • 92
    Neff GW, O'Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002; 97(8): 21179.
    Direct Link:
  • 93
    Tamaki K. Antipruritic effect of macrolide antibiotics. J Dermatol 2000; 27(1): 667.
  • 94
    Komine M, Tamaki K. An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 2000; 27(8): 50812.
  • 95
    Yazawa N, Ihn H, Yamane K, Etoh T, Tamaki K. The successful treatment of prurigo pigmentosa with macrolide antibiotics. Dermatology 2001; 202(1): 679.
  • 96
    Lauterburg BH, Pineda AA, Dickson ER, Baldus WP, Taswell HF. Plasmaperfusion for the treatment of intractable pruritus of cholestasis. Mayo Clin Proc 1978; 53(6): 4037.
  • 97
    Lauterburg BH, Taswell HF, Pineda AA, Dickson ER, Burgstaler EA, Carlson GL. Treatment of pruritus of cholestasis by plasma perfusion through USP-charcoal-coated glass beads. Lancet 1980; 2(8185): 535.
  • 98
    Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985; 26(3): 2914.
  • 99
    Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002; 26(2): 10310.
  • 100
    Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95(1): 1306.
  • 101
    Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31(4): 100513.
  • 102
    Do Valle Gameiro MR, Ampuero SV, Ruaro RT, et al. Pruritus in a patient with anicteric hepatitis: case report. Anais Brasil Dermatol 2001; 76(3): 3036.
  • 103
    Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut 1997; 41(2): 26971.
  • 104
    Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch Dis Child 1993; 69(1): 1413.
  • 105
    Lebovics E, Seif F, Kim D, et al. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci 1997; 42(5): 10949.
  • 106
    Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998; 43(10): 217783.
  • 107
    Kumar KS, Saboorian MH, Lee WM. Cholestatic presentation of chronic hepatitis C: a clinical and histological study with a review of the literature. Dig Dis Sci 2001; 46(10): 206673.
  • 108
    Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis 2000; 32(7): 6215.
  • 109
    Shaw D, Frohlich J, Wittmann BA, Willms M. A prospective study of 18 patients with cholestasis of pregnancy. Am J Obstet Gynecol 1982; 142(6 Part 1): 6215.
  • 110
    Hirvioja ML, Tuimala R, Vuori J. The treatment of intrahepatic cholestasis of pregnancy by dexamethasone. Br J Obstet Gynaecol 1992; 99(2): 10911.
  • 111
    Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998; 28(6): 144953.
  • 112
    Meng LJ, Reyes H, Axelson M, et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology 1997; 26(6): 15739.
  • 113
    Palma J, Reyes H, Ribalta J, et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology 1992; 15(6): 10437.
  • 114
    Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int J Gynaecol Obstet 1996; 52(2): 13340.
  • 115
    Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27(6): 10228.
  • 116
    Nicastri PL, Diaferia A, Tartagni M, Loizzi P, Fanelli M. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol 1998; 105(11): 12057.
  • 117
    Laifer SA, Stiller RJ, Siddiqui DS, Dunston-Boone G, Whetham JC. Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of pregnancy. J Matern Fetal Med 2001; 10(2): 1315.
  • 118
    Floreani A, Paternoster D, Melis A, Grella PV. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur J Obstet Gynecol Reprod Biol 1996; 67(2): 10913.
  • 119
    Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graca LM. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998; 28(1): 918.
  • 120
    Davies MH, Da Silva RC, Jones SR, Weaver JB, Elias E. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut 1995; 37(4): 5804.
  • 121
    Burrows RF, Clavisi O, Burrows E. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2001; 4: CD000493.
  • 122
    Milkiewicz P, Elias E, Williamson C, Weaver J. Obstetric cholestasis. Br Med J 2002; 324(7330): 1234.